Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability…
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for…
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as…
